Evidence memo

GHK-Cu

Also tracked as: Copper peptide GHK-Cu, glycyl-L-histidyl-L-lysine copper

Topical skin and wound-healing contexts have more plausible evidence than broad systemic longevity claims.

Context-dependent Safety watch

Evidence status

Peptide and compound claims to watch. Evidence level: Context-dependent.

Whether GHK-Cu claims are being limited to studied dermatologic contexts or expanded into unsupported systemic anti-aging claims.

It is widely discussed because mechanistic skin-repair narratives sound intuitive and because cosmetic products are common.

The signal is strongest for skin biology and selected topical/cosmetic contexts; outcome evidence is much thinner for broad systemic claims.

Whether product form, purity, delivery context, and endpoint choice materially change risk and benefit.

Topical cosmetic discussion is not the same as systemic therapeutic proof. Product identity and regulatory category matter.

Better controlled human outcome trials, clearer product characterization, and regulatory updates for compounded peptide claims.

Context-dependent: plausible in narrow skin contexts, weak for generalized longevity or recovery narratives.

PubMed

Pickart and Margolina · 2015

Mechanistic and skin-regeneration review; not proof of broad systemic claims.

PubMed

Leyden et al. · 2006

Human cosmetic-dermatology context; does not validate systemic wellness claims.

FDA

U.S. Food and Drug Administration · Current FDA page

Regulatory source for compounding-safety watch items; status should be rechecked before publication.